聚焦血液肿瘤患者CAR-T治疗后细胞因子释放综合征  

CAR-T cell therapy associated cytokine release syndrome in hematologic tumors

作　　者：李凌浩[1] 宫文洁 吴德沛[1] 薛胜利[1] LI Linghao;GONG Wenjie;WU Depei;XUE Shengli(Department of Hematology,the First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Diseases,Suzhou,Jiangsu,215006,China)

机构地区：[1]苏州大学附属第一医院血液科,江苏省血液研究所,国家血液系统疾病临床医学研究中心,江苏苏州215006

出　　处：《临床血液学杂志》2025年第1期77-83,共7页Journal of Clinical Hematology

基　　金：江苏省自然科学基金(No:BK20221235)。

摘　　要：细胞因子释放综合征(cytokine release syndrome, CRS)是嵌合抗原受体(chimeric antigen receptor, CAR)T细胞免疫治疗最主要的并发症,其发病涉及巨噬细胞等释放大量细胞因子损伤相应器官。为尽早识别和应对CRS,探索其预测指标的研究正在积极进行中,新的预防和治疗方法也不断涌现。Cytokine release syndrome(CRS)represents a common and critical complication associated with chimeric antigen receptor(CAR)T cell immunotherapy,characterized by the pathogenesis involving macrophagemediated cytokine overproduction,which subsequently leads to organ damage,To facilitate early identification and intervention of CRS,ongoing research is focused on elucidating its predictive markers,alongside the development of novel preventive and therapeutic strategies.

关 键 词：细胞因子释放综合征 嵌合抗原受体T细胞 血液肿瘤 

分 类 号：R733[医药卫生—肿瘤]